Aromatase Inhibitors: Past, Present and Future
Author Information
Author(s): Bertelli G
Primary Institution: South West Wales Cancer Institute
Hypothesis
What is the optimal sequence for hormonal therapy in breast cancer?
Conclusion
Current evidence suggests that using aromatase inhibitors in sequence can prolong disease control in breast cancer treatment.
Supporting Evidence
- Anastrozole was found to be more effective than tamoxifen in the early adjuvant setting.
- Sequential use of tamoxifen followed by an AI showed improved disease-free survival.
- Combination therapy did not provide advantages over single agents in the ATAC study.
- Exemestane after tamoxifen therapy resulted in a significant reduction in disease-free survival events.
- Clinical benefit rates were reported for various sequences of aromatase inhibitors.
Takeaway
Doctors are trying to figure out the best order to give different medicines to help women with breast cancer feel better for a longer time.
Methodology
The study reviews various trials and studies on the sequencing of aromatase inhibitors in breast cancer treatment.
Limitations
The study does not provide clear clinical differences between steroidal and nonsteroidal AIs, and ongoing trials are needed for more definitive conclusions.
Participant Demographics
Postmenopausal women with advanced breast cancer.
Statistical Information
P-Value
P<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website